Key Takeaways
- • Hoxton Farms opened the UK's first cultivated animal fat pilot production facility on September 21, 2023, a 14,000-square-foot site in Old Street, central London, with capacity of up to 10 tons per year.
- • The facility includes specialized cell culture laboratories, a food development kitchen, and a hardware workshop for manufacturing bioreactors, designed to advance research and production of cultivated fat derived from pig stem cells.
- • Hoxton Farms raised $22 million in Series A funding to support the pilot facility development and is targeting price parity with plant-based oils as a near-term commercial objective.
- • The company positions cultivated animal fat as a critical missing ingredient for plant-based meat products, addressing a key technical limitation in the alternative protein sector.
- • The London location demonstrates the company's strategy to prove that cultivated fat production can be established in multiple geographic markets, not solely in specialized biotech hubs.
Summary
Hoxton Farms, a London-based biotech company specializing in cultivated animal fat, officially opened its pilot production facility on September 21, 2023, marking the first facility of its kind in the United Kingdom. The 14,000-square-foot site, located in Old Street in central London, represents a significant operational milestone for the cultivated meat sector and signals growing commercial viability of cellular agriculture technology beyond protein production.
The facility is engineered with specialized infrastructure including cell culture laboratories, a food development kitchen, and a dedicated hardware workshop for manufacturing bioreactors. This design reflects the company's integrated approach to moving from research and development into scaled production. The facility has an annual production capacity of up to 10 tons, positioning it as a demonstration-scale operation designed to validate commercial processes before full-scale manufacturing.
Hoxton Farms' core technology begins with stem cells derived from pigs—described as the natural precursor to traditional pork fat—which are cultivated using a proprietary blend of plant-based nutrients. The company's strategic positioning addresses what it identifies as a critical gap in plant-based meat products: the inability of plant-based alternatives to accurately replicate the sensory and functional properties of animal fat. This technical differentiation provides the company with a distinct market application within the broader alternative protein landscape.
The company raised $22 million in Series A funding to support the pilot facility's development and operations. Management has publicly stated that the company is on track to achieve price parity with plant-based oils, a crucial commercial threshold for market adoption. The central London location was deliberately chosen to demonstrate that cultivated fat production can be established in diverse geographic markets, reducing dependency on specialized biotech clusters and signaling scalability of the model across regions.
The facility is engineered with specialized infrastructure including cell culture laboratories, a food development kitchen, and a dedicated hardware workshop for manufacturing bioreactors. This design reflects the company's integrated approach to moving from research and development into scaled production. The facility has an annual production capacity of up to 10 tons, positioning it as a demonstration-scale operation designed to validate commercial processes before full-scale manufacturing.
Hoxton Farms' core technology begins with stem cells derived from pigs—described as the natural precursor to traditional pork fat—which are cultivated using a proprietary blend of plant-based nutrients. The company's strategic positioning addresses what it identifies as a critical gap in plant-based meat products: the inability of plant-based alternatives to accurately replicate the sensory and functional properties of animal fat. This technical differentiation provides the company with a distinct market application within the broader alternative protein landscape.
The company raised $22 million in Series A funding to support the pilot facility's development and operations. Management has publicly stated that the company is on track to achieve price parity with plant-based oils, a crucial commercial threshold for market adoption. The central London location was deliberately chosen to demonstrate that cultivated fat production can be established in diverse geographic markets, reducing dependency on specialized biotech clusters and signaling scalability of the model across regions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.